Avalo Therapeutics (NASDAQ:AVTX) Releases Quarterly Earnings Results, Misses Expectations By $0.27 EPS

Avalo Therapeutics (NASDAQ:AVTX) released its earnings results on Thursday. The company reported ($0.83) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.56) by ($0.27), FiscalAI reports.

Avalo Therapeutics Stock Performance

AVTX stock traded down $0.14 during midday trading on Thursday, reaching $18.70. 596,212 shares of the company traded hands, compared to its average volume of 872,402. The firm has a market capitalization of $989.23 million, a price-to-earnings ratio of -3.42 and a beta of 0.80. Avalo Therapeutics has a 52-week low of $8.01 and a 52-week high of $24.27. The business has a 50 day moving average of $17.22 and a 200-day moving average of $16.27.

Analysts Set New Price Targets

AVTX has been the topic of several recent analyst reports. BTIG Research reissued a “buy” rating and set a $58.00 target price on shares of Avalo Therapeutics in a research note on Tuesday, June 16th. Piper Sandler reiterated an “overweight” rating and set a $60.00 price objective (up from $48.00) on shares of Avalo Therapeutics in a research report on Monday, May 11th. Citizens Jmp lowered their target price on shares of Avalo Therapeutics from $62.00 to $55.00 and set a “market outperform” rating on the stock in a report on Thursday, May 14th. Mizuho upped their target price on shares of Avalo Therapeutics from $39.00 to $45.00 and gave the stock an “outperform” rating in a research report on Thursday, May 14th. Finally, Citigroup reaffirmed an “outperform” rating on shares of Avalo Therapeutics in a research note on Wednesday, May 6th. Thirteen investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $45.80.

Insider Activity at Avalo Therapeutics

In other news, insider Mittie Doyle sold 1,450 shares of Avalo Therapeutics stock in a transaction that occurred on Tuesday, June 23rd. The stock was sold at an average price of $18.00, for a total value of $26,100.00. Following the completion of the transaction, the insider owned 51,776 shares in the company, valued at approximately $931,968. The trade was a 2.72% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 4.46% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of the company. Dimensional Fund Advisors LP purchased a new stake in shares of Avalo Therapeutics in the third quarter valued at $143,000. Boothbay Fund Management LLC bought a new position in Avalo Therapeutics during the 2nd quarter valued at about $56,000. Jump Financial LLC purchased a new stake in Avalo Therapeutics in the 4th quarter worth about $238,000. Persistent Asset Partners Ltd bought a new stake in Avalo Therapeutics in the fourth quarter worth about $274,000. Finally, Hudson Bay Capital Management LP bought a new stake in Avalo Therapeutics in the fourth quarter worth about $305,000. 87.06% of the stock is owned by hedge funds and other institutional investors.

Avalo Therapeutics Company Profile

Avalo Therapeutics is a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for cardiometabolic, fibrotic and inflammatory diseases. The company’s proprietary drug-design platform enables the creation of long-acting prodrugs with optimized pharmacokinetic profiles, aiming to improve efficacy, safety and patient adherence. By leveraging this technology, Avalo seeks to address key drivers of disease progression that remain underserved by existing treatments.

Its lead programs include AVTX-002, a first-in-class prodrug candidate designed to inhibit angiotensinogen for the treatment of hypertension and related cardiovascular disorders, and AVTX-006, an early-stage candidate targeting pathways implicated in fibrosis and metabolic dysfunction.